• Explore /
  • Poster
  • / GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.

Abstract Poster

Authors

null

Krishnansu Sujata Tewari

The Division of Gynecologic Oncology at the University of California, Irvine, Orange, CA

Krishnansu Sujata Tewari , Ignace Vergote , Ana Oaknin , Edwin Alvarez , Dana Meredith Chase , Stephanie Gaillard , Stephanie Lheureux , Danny Rischin , Alessandro Santin , Minjie Feng , Melissa Mathias , Matthew G. Fury , Israel Lowy , Bradley J. Monk

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT03257267

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS5600)

DOI

10.1200/JCO.2018.36.15_suppl.TPS5600

Abstract #

TPS5600

Poster Bd #

327a

Abstract Disclosures

Similar Posters

First Author: Ignace Vergote

First Author: Luis Manso

First Author: Thomas J. Herzog

First Author: Akihiro Ohba